You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 117 No. 3, March 1991 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL ARTICLES
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

5-Year Results of Cisplatin and Fluorouracil Infusion in Head and Neck Cancer

John R. Jacobs, MD; Karen K. Fu, MD; Louis D. Lowry, MD; R. L. Scotte Doggett, MD; Thomas F. Pajak, PhD; Muhyi Al-Sarraf, MD

Arch Otolaryngol Head Neck Surg. 1991;117(3):288-291.


Abstract

• As part of the developmental process for the Head and Neck Intergroup trial of adjuvant chemotherapy for advanced resectable head and neck carcinoma, in 1981 the Radiation Therapy Oncology Group, Philadelphia, Pa, conducted two nonrandomized pilot studies using chemotherapy consisting of three courses of cisplatin and fluorouracil infusion. Chemotherapy was administered prior to surgery in 42 patients (induction) and after surgery in an additional 29 patients (sequential). The populations were roughly comparable with respect to tumor site and stage. Twelve of the 42 patients in the induction group and seven of the 29 in the sequential group are alive and with no evidence of disease at the last reported follow-up. The median survival was 31 months in the sequential group vs 20 months in the induction group. Only two of the 26 patients with less than a complete clinical response following induction chemotherapy are still alive. Twenty-seven of the 42 patients who received induction chemotherapy did not undergo surgery as initially planned. Despite the lack of surgery, at 5 years the survival between the two groups was not significantly different (27% for the induction group vs 23% for the sequential group).

(Arch Otolaryngol Head Neck Surg. 1991;117:288-291)



Author Affiliations

From the Department of Otolaryngology (Dr Jacobs) and Division of Oncology (Dr Al-Sarraf), Wayne State University, Detroit, Mich; Department of Radiation Oncology, University of California, San Francisco (Dr Fu); Department of Otolaryngology, Jefferson Medical College, Philadelphia, Pa (Dr Lowry); Department of Radiation Oncology, Sutter Community Hospital, Sacramento, Calif (Dr Scotte Doggett); and Radiation Therapy Oncology Group, American College of Radiology, Philadelphia, Pa (Dr Pajak).


Footnotes

Accepted for publication September 4, 1990.

Reprints not available.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Polymer Delivery of Chemotherapy for Squamous Cell Carcinoma of the Head and Neck
Shikani et al.
Arch Otolaryngol Head Neck Surg 1994;120:1242-1247.
ABSTRACT  

Simultaneous Chemoradiation in the Treatment of Advanced Head and Neck Cancer
Weissler et al.
Arch Otolaryngol Head Neck Surg 1992;118:806-810.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1991 American Medical Association. All Rights Reserved.